Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction
0301 basic medicine
0303 health sciences
03 medical and health sciences
Soluble Guanylyl Cyclase
0302 clinical medicine
Fibrinolytic Agents
Guanylate Cyclase
Vasodilator Agents
Myocardial Infarction
Animals
Humans
Nitric Oxide
Rats
DOI:
10.1007/s10517-022-05461-y
Publication Date:
2022-05-02T18:02:42Z
AUTHORS (9)
ABSTRACT
New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (14)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....